Newron Pharmaceuticals S.p.A.

SWX:NWRN Stock Report

Market Cap: CHF 263.0m

Newron Pharmaceuticals Valuation

Is NWRN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of NWRN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: NWRN (CHF13.04) is trading below our estimate of future cash flow value (CHF114.11)

Significantly Below Future Cash Flow Value: NWRN is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NWRN?

Key metric: As NWRN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NWRN. This is calculated by dividing NWRN's market cap by their current revenue.
What is NWRN's PS Ratio?
PS Ratio15.4x
Sales€19.13m
Market Cap€285.24m

Price to Sales Ratio vs Peers

How does NWRN's PS Ratio compare to its peers?

The above table shows the PS ratio for NWRN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average19.8x
BIOV BioVersys
48.9x68.27%CHF 152.2m
CURN Curatis Holding
10.6xn/aCHF 117.6m
COPN Cosmo
11.2x26.71%CHF 1.1b
DESN Dottikon ES Holding
8.7x13.81%CHF 3.8b
NWRN Newron Pharmaceuticals
15.4x38.18%CHF 263.0m

Price-To-Sales vs Peers: NWRN is good value based on its Price-To-Sales Ratio (15.4x) compared to the peer average (19.8x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does NWRN's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

19 CompaniesPrice / SalesEstimated GrowthMarket Cap
NWRN 15.4xIndustry Avg. 4.1xNo. of Companies23PS048121620+
19 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NWRN is expensive based on its Price-To-Sales Ratio (15.4x) compared to the European Pharmaceuticals industry average (4.1x).

Price to Sales Ratio vs Fair Ratio

What is NWRN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NWRN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio15.4x
Fair PS Ratio18.9x

Price-To-Sales vs Fair Ratio: NWRN is good value based on its Price-To-Sales Ratio (15.4x) compared to the estimated Fair Price-To-Sales Ratio (18.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NWRN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 13.04
CHF 47.35
+263.10%
31.98%CHF 72.98CHF 35.27n/a4
Jun ’27CHF 13.08
CHF 47.10
+260.07%
31.84%CHF 72.41CHF 34.99n/a4
May ’27CHF 14.30
CHF 48.07
+236.19%
30.96%CHF 72.37CHF 34.97n/a4
Apr ’27CHF 15.50
CHF 48.41
+212.33%
31.50%CHF 73.33CHF 34.95n/a4
Mar ’27CHF 18.60
CHF 47.42
+154.93%
29.50%CHF 71.42CHF 36.83n/a4
Feb ’27CHF 19.48
CHF 40.30
+106.86%
47.61%CHF 71.62CHF 11.27n/a5
Jan ’27CHF 23.85
CHF 30.62
+28.40%
70.93%CHF 72.97CHF 11.48n/a5
Dec ’26CHF 19.44
CHF 18.08
-6.98%
26.79%CHF 23.02CHF 11.50n/a3
Nov ’26CHF 14.44
CHF 18.08
+25.22%
26.79%CHF 23.02CHF 11.50n/a3
Oct ’26CHF 10.92
CHF 18.04
+65.23%
26.74%CHF 22.96CHF 11.49n/a3
Sep ’26CHF 8.75
CHF 18.20
+107.95%
27.09%CHF 23.20CHF 11.49n/a3
Aug ’26CHF 6.89
CHF 18.03
+161.75%
27.67%CHF 23.14CHF 11.26n/a3
Jul ’26CHF 6.74
CHF 17.86
+165.00%
27.65%CHF 23.23CHF 11.31n/a3
Jun ’26CHF 7.32
CHF 17.86
+144.01%
27.65%CHF 23.23CHF 11.31CHF 13.083
May ’26CHF 7.16
CHF 17.63
+146.20%
27.77%CHF 22.97CHF 11.14CHF 14.303
Apr ’26CHF 7.55
CHF 15.81
+109.34%
19.69%CHF 18.75CHF 11.50CHF 15.503
Mar ’26CHF 9.90
CHF 15.64
+58.00%
19.11%CHF 18.49CHF 11.51CHF 18.603
Feb ’26CHF 9.46
CHF 15.64
+65.35%
19.11%CHF 18.49CHF 11.51CHF 19.483
Jan ’26CHF 8.95
CHF 14.39
+60.73%
12.44%CHF 16.86CHF 12.70CHF 23.853
Dec ’25CHF 7.74
CHF 14.42
+86.28%
12.56%CHF 16.94CHF 12.76CHF 19.443
Nov ’25CHF 8.20
CHF 14.42
+75.83%
12.56%CHF 16.94CHF 12.76CHF 14.443
Oct ’25CHF 7.70
CHF 14.42
+87.25%
12.56%CHF 16.94CHF 12.76CHF 10.923
Sep ’25CHF 8.50
CHF 14.30
+68.23%
15.23%CHF 17.31CHF 12.23CHF 8.753
Aug ’25CHF 8.48
CHF 14.30
+68.62%
15.23%CHF 17.31CHF 12.23CHF 6.893
Jul ’25CHF 8.84
CHF 14.30
+61.75%
15.23%CHF 17.31CHF 12.23CHF 6.743
Jun ’25CHF 10.00
CHF 14.45
+44.50%
14.27%CHF 17.29CHF 12.46CHF 7.323
CHF 47.35
Fair Value
72.5% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/30 18:59
End of Day Share Price 2026/06/30 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Newron Pharmaceuticals S.p.A. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jyoti PrakashEdison Investment Research
Raghuram SelvarajuH.C. Wainwright & Co.
Lucy CodringtonJefferies LLC